Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials

Area of Science:

• Dermatology
• Pharmacology
• Clinical Trial Analysis

Background:

• Atopic dermatitis (AD) pathogenesis involves multiple pathways, leading to diverse treatment strategies.
• Numerous topical, biologic, and systemic agents targeting AD have been developed.
• Understanding treatment failures is crucial for advancing AD therapeutics.

Purpose of the Study:

• To review the mechanisms of action and study designs of agents that failed AD clinical trials.
• To identify reasons for treatment failures and extract lessons for future drug development.
• To analyze specific classes of agents including PDE-4 inhibitors, CRTH2 inhibitors, and monoclonal antibodies.

Main Methods:

• Searched Clinicaltrials.gov for completed, placebo-controlled Phase II and III AD trials that missed primary endpoints.
• Included only Phase II trials for detailed analysis.
• Supplemented data with PubMed searches for agents with known mechanisms of action.

Main Results:

• Analysis focused on apremilast, roflumilast (PDE-4 inhibitors), fevipiprant, temapiprant (CRTH2 inhibitors), and tezepelumab, ustekinumab (monoclonal antibodies).
• Examined mechanisms of action, study designs, and patient demographics of failed trials.
• Identified potential reasons for lack of efficacy in AD.

Conclusions:

• Agents failing in AD trials may retain therapeutic value for specific patient subgroups or other conditions.
• Further investigation into subgroup analyses from previous trials may be warranted.
• Continued research into AD pathophysiology is essential for optimizing future therapeutic strategies.